SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002; 347: 589600.
  • 2
    Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001; 60: 831846.
  • 3
    Symmers WS. Thrombotic microangiopathy (thrombotic thrombocytopenic purpura) associated with acute haemorrhagic leucoencephalitis and sensitivity to oxophenarsine. Brain. 1956; 79: 511521.
  • 4
    Murgo AJ. Cancer- and chemotherapy-associated thrombotic microangiopathy. In: KaplanBS, TrompeterRS, MoakeJL, editors. Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. New York: Marcel Dekker, 1992: 271285.
  • 5
    Lesesne JB, Rothschild N, Erickson B, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol. 1989; 7: 781789.
  • 6
    Murgo AJ. Thrombotic microangiopthy in the cancer patient including those induced by chemotherapeutic agents. Semin Hematol. 1987; 24: 161177.
  • 7
    Pisoni R, Ruggenenti P, Remuzzi G. Drug-induced thrombotic microangiopathy. Drug Saf. 2001; 24: 491501.
  • 8
    Eli Lilly and Company. 2001 annual report. Indianapolis: Eli Lilly, 2002.
  • 9
    Walter RB, Joerger M, Pestalozzi BC. Gemcitabine-associated hemolytic-uremic syndrome. Am J Kidney Dis. 2002; 40: E16.
  • 10
    Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer. 1999; 85: 20232032.
  • 11
    Remuzzi G, Ruggenenenti P, Bertani P. Thrombotic microangiopathy. In: TisherCC, BrennerBM, editors. Renal pathology. Philadelphia: Lippincott Williams & Wilkins, 1994: 11541184.
  • 12
    Eli Lilly and Company. Gemzar® [product label]. Indianapolis: Eli Lilly, 2003.
  • 13
    Ruggenenti P, Remuzzi G. Malignant vascular disease of the kidney: nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy. Am J Kidney Dis. 1996; 27: 459475.
  • 14
    D'Agati VD, Cannon PJ. Scleroderma (systemic sclerosis). In: TisherCC, BrennerBM, editors. Renal pathology. Philadelphia: Lippincott Williams & Wilkins, 1994: 10581086.
  • 15
    Habib R, Gagnadoux MF, Broyer M. [Hemolytic uremic syndrome in children and arteriolar hypertension]. Arch Mal Coeur Vaiss. 1981; 74: 3743.
  • 16
    Morel-Maroger L, Kanfer A, Solez K, Sraer JD, Richet G. Prognostic importance of vascular lesions in acute renal failure with microangiopathic hemolytic anemia (hemolytic uremic syndrome): clinicopathologic study in 20 adults. Kidney Int. 1979; 15: 548558.
  • 17
    Cannon PJ, Hassan M, Case DB, Casarella WJ, Sommers SC, LeRoy EC. The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine (Baltimore). 1974; 53: 146.
  • 18
    Harrell RM, Sibley R, Vogelzang NJ. Renal vascular lesions after chemotherapy with vinblastine, bleomycin, and cisplatin. Am J Med. 1982; 73: 429433.
  • 19
    Raife TJ, Lager DJ. Chronic thrombotic microangiopathy associated with antineoplastic therapy with minimal hematologic effects. Mayo Clin Proc. 2002; 77: 323328.
  • 20
    Flombaum CD, Mouradian JA, Casper ES, Erlandson RA, Benedetti F. Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine. Am J Kidney Dis. 1999; 33: 555562.
  • 21
    Schwimmer J, Nadasdy TA, Spitalnik PF, Kaplan KL, Zand MS. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome and localized renal thrombotic microangiopathy. Am J Kidney Dis. 2003; 41: 471479.
  • 22
    Cohen EP. Radiation nephropathy after bone marrow transplantation. Kidney Int. 2000; 58: 903918.
  • 23
    Trimarchi HM, Truong LD, Brennan S, Gonzalez JM, Suki WN. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. Transplantation. 1999; 67: 539544.
  • 24
    Pham PT, Peng A, Wilkenson AH, et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis. 2000; 36: 844850.
  • 25
    Green MR. Gemcitabine safety overview. Semin Oncol. 1996; 23: 3235.